News Archives - Ethyreal Bio

Ethyreal Bio Achieves Proof of Mechanism in First-in-Human Study of ETHY-001 and Initiates First Patient Cohorts to Advance Development in Thyroid Eye Disease (TED) and Graves’ Disease (GD)

CAMBRIDGE, Mass., October 19, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology compan...

By Daniel Nunez|2026-10-16T15:09:52-04:00October 19, 2026|News|0 Comments

Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED

CAMBRIDGE, Mass., June 15, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...

By Daniel Nunez|2026-07-16T13:27:05-04:00June 15, 2026|News|0 Comments

Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease

CAMBRIDGE, Mass., June 10, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...

By Daniel Nunez|2026-06-10T07:28:31-04:00June 10, 2026|News|0 Comments

Ethyreal Bio, Inc.

700 Technology Sq, FL 3
Cambridge, MA 02139
United States

700 Technology Sq, FLR 3
Cambridge, MA 02139
United States

ETHY-001 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Its safety and efficacy have not been established. The information on this website is intended for educational purposes and does not constitute medical advice. Please consult your healthcare provider with any questions about your condition or treatment.